# Fennec Pharmaceuticals Inc.: overview FENC · Nasdaq · CIK 1211583 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/fenc.md) · [Financials](/companies/fenc/financials.md) · [Filings](/companies/fenc/filings.md) · [Insiders](/companies/fenc/insiders.md) Latest reported revenue: [$17.9m](/filings/0001104659-26-095884.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:Revenues, accession 0001104659-26-095884). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [7.0](/filings/0001104659-25-111260.md) | [7.9 d](/filings/0001104659-26-036182.md) | [8.8](/filings/0001104659-26-061213.md) | [9.7](/filings/0001104659-26-095884.md) | [12.5](/filings/0001104659-25-111260.md) | [13.8 d](/filings/0001104659-26-036182.md) | [15.1](/filings/0001104659-26-061213.md) | [17.9](/filings/0001104659-26-095884.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(74.6%)](/filings/0001104659-25-111260.md) | [(11.8%) d](/filings/0001104659-26-036182.md) | [(9.2%)](/filings/0001104659-26-061213.md) | [(28.3%)](/filings/0001104659-26-095884.md) | [(1.5%)](/filings/0001104659-25-111260.md) | [(18.5%) d](/filings/0001104659-26-036182.md) | [(0.8%)](/filings/0001104659-26-061213.md) | [9.7%](/filings/0001104659-26-095884.md) | | Net margin | % | [(82.2%)](/filings/0001104659-25-111260.md) | [(25.0%) d](/filings/0001104659-26-036182.md) | [(13.3%)](/filings/0001104659-26-095884.md) | [(32.7%)](/filings/0001104659-26-095884.md) | [(5.1%)](/filings/0001104659-25-111260.md) | [(34.7%) d](/filings/0001104659-26-036182.md) | [1.3%](/filings/0001104659-26-095884.md) | [11.0%](/filings/0001104659-26-095884.md) | | Diluted EPS | $ per share | [(0.21)](/filings/0001104659-25-111260.md) | not reported | [(0.04)](/filings/0001104659-26-061213.md) | [(0.11)](/filings/0001104659-26-095884.md) | [(0.02)](/filings/0001104659-25-111260.md) | not reported | [0.01](/filings/0001104659-26-061213.md) | [0.05](/filings/0001104659-26-095884.md) | | Free cash flow | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | [1.5](/filings/0001558370-24-004383.md) | [21.3](/filings/0001558370-25-003710.md) | [47.5](/filings/0001104659-26-036182.md) | [44.6](/filings/0001104659-26-036182.md) | | Gross margin | % | not reported | [94.4%](/filings/0001558370-24-004383.md) | [94.1%](/filings/0001558370-24-004383.md) | not reported | not reported | | Operating margin | % | not reported | [(1471.6%)](/filings/0001558370-24-004383.md) | [(60.1%)](/filings/0001558370-25-003710.md) | [5.4%](/filings/0001104659-26-036182.md) | [(14.1%)](/filings/0001104659-26-036182.md) | | Net margin | % | not reported | [(1544.9%)](/filings/0001558370-24-004383.md) | [(75.5%)](/filings/0001558370-25-003710.md) | [(0.9%)](/filings/0001104659-26-036182.md) | [(21.8%)](/filings/0001104659-26-036182.md) | | Diluted EPS | $ per share | [(0.67)](/filings/0001558370-23-004948.md) | [(0.90)](/filings/0001558370-24-004383.md) | [(0.60)](/filings/0001558370-25-003710.md) | [(0.02)](/filings/0001104659-26-036182.md) | [(0.34)](/filings/0001104659-26-036182.md) | | Free cash flow | $m | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/fenc/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Rosalind Advisors, Inc.](/funds/1622627.md) | 2026-06-30 | $34.3m | 3,188,001 | | Added +279,800 | | [AIGH Capital Management LLC](/funds/1835943.md) | 2026-06-30 | $26.7m | 2,486,038 | | Added +504,537 | | [Solas Capital Management, LLC](/funds/1604867.md) | 2026-06-30 | $20.3m | 1,889,366 | | Reduced −592,832 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $18.6m | 1,727,069 | | Added +358,893 | | [AWM Investment Company, Inc.](/funds/1535264.md) | 2026-06-30 | $12.5m | 1,160,296 | | Added +440,161 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $9.0m | 839,306 | | Reduced −57,838 | | [Prospect Capital Advisors, LLC](/funds/1632368.md) | 2026-06-30 | $5.4m | 497,800 | | New +497,800 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $4.6m | 426,004 | | Added +66,949 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $4.3m | 402,566 | | Added +30,828 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $2.5m | 233,877 | | New +233,877 | ## Recent filings [All 726 filings](/companies/fenc/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-17 | 20:03 ET | [8-K](/filings/0001104659-26-108565.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-108565 | | 2026-08-13 | 20:03 ET | [10-Q](/filings/0001104659-26-095884.md) | Quarterly report, period 2026-06-30 | 0001104659-26-095884 | | 2026-06-10 | 21:19 ET | [8-K](/filings/0001104659-26-072425.md) | 5.07 Shareholder vote results | 0001104659-26-072425 | | 2026-05-22 | 20:05 ET | [8-K](/filings/0001104659-26-065696.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-065696 | | 2026-05-18 | 21:12 ET | [8-K](/filings/0001104659-26-063271.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001104659-26-063271 | | 2026-05-14 | 20:24 ET | [10-Q](/filings/0001104659-26-061213.md) | Quarterly report, period 2026-03-31 | 0001104659-26-061213 | | 2026-04-28 | 20:46 ET | [8-K](/filings/0001104659-26-050433.md) | 5.02 Departure or appointment of officers or directors | 0001104659-26-050433 | | 2026-04-28 | 20:09 ET | [DEF 14A](/filings/0001104659-26-050339.md) | Proxy statement, period 2026-06-10 | 0001104659-26-050339 | | 2026-04-22 | 20:05 ET | [8-K](/filings/0001104659-26-046804.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-046804 | | 2026-04-07 | 20:27 ET | [8-K](/filings/0001104659-26-040414.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-040414 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-036182.md), filed Mar 27, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/5e407f3c-d622-4968-a0eb-9ecc8f67c814) ## About the filer - CIK: 1211583 - Tickers: FENC - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: A1 - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:35 ET. No prices; not investment advice.